Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shareholder Notice: Investigation over Possible Violations of Securities Laws
An investigation for investors in Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares over potential securities laws violations by Fennec Pharmaceuticals Inc. was announced.
San Diego, CA -- (SBWire) -- 09/02/2020 --An investigation was announced concerning potential securities laws violations by Fennec Pharmaceuticals Inc. in connection with certain financial statements.
Investors who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Fennec Pharmaceuticals Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Research Triangle, Park, NC based Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States.
On August 11, 2020, Fennec Pharmaceuticals Inc. disclosed that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for PEDMARK, a formulation of sodium thiosulfate for intravenous administration for the ototoxicity associated with cisplatin chemotherapy. According to the CRL, "after recent completion of a pre-approval inspection of the manufacturing facility of [Fennec's] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK."
Shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) declined from $10.67 per share on August 10, 2020, to as low as $5.12 per share on August 25, 2020.
Those who purchased shares of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
Michael Daniels
Shareholders Foundation
1-858-779-1554
https://shareholdersfoundation.com/
View this press release online at: http://rwire.com/1302485